US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Carisma Therapeutics

0.2185

+0.00331.53%

Volume:40.08K

Turnover:8.52K

Market Cap:9.13M

PE:-0.15

High:0.2209

Open:0.2190

Low:0.2081

Close:0.2152

Loading ...

Overview Company News Filings

BRIEF-Carisma Therapeutics Announces Restructuring

Carisma Therapeutics Inc - Chief Financial Officer, Richard Morris Will Leave Company Effective Dec 31

THOMSON REUTERS

Carisma Therapeutics Announces Strategic Restructuring to Re-Prioritize Pipeline

THOMSON REUTERS

Carisma Therapeutics Inc - Expects $2.7 Million Cost for Workforce Reduction

THOMSON REUTERS

Carisma Therapeutics Inc -Development of Ct-0525 to Be Discontinued; Workforce Reduced by 34%

THOMSON REUTERS

Press Release: Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Carisma Therapeutics Is Maintained at Buy by D. Boral Capital

Carisma Therapeutics Says Preclinical Data Support Potential of Engineered Macrophages to Treat Liver Fibrosis

MT Newswires Live

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024

Carisma Therapeutics Is Maintained at Buy by D. Boral Capital

Optimistic Buy Rating for Carisma Therapeutics Amid Promising CAR-Myeloid Developments and Strong Financial Standing

Carisma Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

BRIEF-Carisma Unveils Pre-Clinical Data On Anti-GPC3 In Vivo CAR-M Therapy For Hepatocellular Carcinoma

Carisma Unveils Promising Pre-Clinical Data on Anti-Gpc3 in Vivo Car-M Therapy for Hepatocellular Carcinoma

THOMSON REUTERS

Carisma -Anti-Gpc3 in Vivo Car-M Therapy Well Tolerated in Mouse Models, Highlighting Its Potential as an off--Shelf Treatment for Gpc3+ Solid Tumors

THOMSON REUTERS

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Carisma Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Carisma Therapeutics Is Maintained at Buy by EF Hutton

CARISMA Therapeutics' Q3 Cash And Cash Equivalents Of $26.9M Expected To Fund The Company Into The Third Quarter Of 2025

Carisma Therapeutics Inc: Cash & Cash Equivalents of $26.9 Million Expected to Fund Co Into Q3 of 2025

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CARM/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CARM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CARM\",,,,,undefined,":{"symbol":"CARM","market":"US","secType":"STK","nameCN":"Carisma Therapeutics","latestPrice":0.2185,"timestamp":1745598744915,"preClose":0.2152,"halted":0,"volume":40082,"delay":0,"floatShares":30260519,"shares":41788096,"eps":-1.458816,"marketStatus":"Trading","change":0.0033,"latestTime":"04-25 12:44:01 EDT","open":0.219,"high":0.2209,"low":0.2081,"amount":8517.21577196,"amplitude":0.05948,"askPrice":0.2185,"askSize":2,"bidPrice":0.2123,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.458816,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745611200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.2152,"postHourTrading":{"tag":"盘后","latestPrice":0.225,"preClose":0.2152,"latestTime":"18:30 EDT","volume":114,"amount":25.65,"timestamp":1745533848971},"volumeRatio":0.453471},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CARM\",,,,,undefined,":{"symbol":"CARM","floatShares":30260519,"roa":"-62.68%","roe":"-362.79%","lyrEps":-1.458816,"volumeRatio":0.453471,"shares":41788096,"dividePrice":0,"high":0.2209,"amplitude":0.05948,"preClose":0.2152,"low":0.2081,"week52Low":0.1601,"pbRate":"-0.33","psRate":"0.47","week52High":1.9,"institutionHeld":0,"latestPrice":0.2185,"committee":0.960784,"eps":-1.458816,"divideRate":0,"volume":40082,"delay":0,"ttmEps":-1.458816,"open":0.219,"prevYearClose":0.4188,"prevWeekClose":0.192,"prevMonthClose":0.31,"prevQuarterClose":0.31,"fiveDayClose":0.192,"twentyDayClose":0.3578,"sixtyDayClose":0.5047},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CARM\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2490278847","title":"BRIEF-Carisma Therapeutics Announces Restructuring","url":"https://stock-news.laohu8.com/highlight/detail?id=2490278847","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490278847?lang=en_us&edition=fundamental","pubTime":"2024-12-09 21:35","pubTimestamp":1733751321,"startTime":"0","endTime":"0","summary":"Dec 9  - Carisma Therapeutics   :   * CARISMA THERAPEUTICS ANNOUNCES STRATEGIC RESTRUCTURING TO RE-PRIORITIZE PIPELINE   * CARISMA THERAPEUTICS INC -DEVELOPMENT OF CT-0525 TO BE DISCONTINUED; WORKFORCE REDUCED BY 34%   * CARISMA THERAPEUTICS INC - EXPECTS $2.7 MILLION COST FOR WORKFORCE REDUCTION   * CARISMA THERAPEUTICS INC - CHIEF FINANCIAL OFFICER, RICHARD MORRIS WILL LEAVE COMPANY EFFECTIVE DEC 31Source text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARM","BK4139"],"gpt_icon":0},{"id":"2490722242","title":"Carisma Therapeutics Inc - Chief Financial Officer, Richard Morris Will Leave Company Effective Dec 31","url":"https://stock-news.laohu8.com/highlight/detail?id=2490722242","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490722242?lang=en_us&edition=fundamental","pubTime":"2024-12-09 21:30","pubTimestamp":1733751004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nTUAYPFX4:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CARM","BK4139"],"gpt_icon":0},{"id":"2490722214","title":"Carisma Therapeutics Announces Strategic Restructuring to Re-Prioritize Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2490722214","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490722214?lang=en_us&edition=fundamental","pubTime":"2024-12-09 21:30","pubTimestamp":1733751004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nTUAYPFX4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CARM"],"gpt_icon":0},{"id":"2490472226","title":"Carisma Therapeutics Inc - Expects $2.7 Million Cost for Workforce Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2490472226","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490472226?lang=en_us&edition=fundamental","pubTime":"2024-12-09 21:30","pubTimestamp":1733751004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nTUAYPFX4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CARM"],"gpt_icon":0},{"id":"2490216722","title":"Carisma Therapeutics Inc -Development of Ct-0525 to Be Discontinued; Workforce Reduced by 34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490216722","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490216722?lang=en_us&edition=fundamental","pubTime":"2024-12-09 21:30","pubTimestamp":1733751004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nTUAYPFX4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CARM","BK4139"],"gpt_icon":0},{"id":"2490722788","title":"Press Release: Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2490722788","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490722788?lang=en_us&edition=fundamental","pubTime":"2024-12-09 21:30","pubTimestamp":1733751000,"startTime":"0","endTime":"0","summary":"Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies. Development of CT-0525 to be discontinued; workforce reduced by 34%. PHILADELPHIA, Dec. 9, 2024 /PRNewswire/ -- Carisma Therapeutics Inc.  , a leader in macrophage-focused therapeutics, today announced a strategic reprioritization of its pipeline, cessation of development of CT-0525, and a reduction in the workforce by 34%. These measures will enable Carisma to focus its resources on advancing its in vivo macrophage engineering platform for the development of fibrosis, oncology and autoimmune disease therapies. This decision aligns Carisma's efforts with next-generation, high-potential programs addressing significant unmet patient needs while enhancing operational efficiency.\"Following a comprehensive review of our portfolio, we have made the strategic decision to prioritize advancing our in vivo macrophage engineering platform,\" said Steven Kelly, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARM","R","BK4232","BK4022","BK4139"],"gpt_icon":0},{"id":"2484982876","title":"Carisma Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2484982876","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484982876?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:54","pubTimestamp":1731966840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CARM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2024 16:54 ET (21:54 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARM"],"gpt_icon":0},{"id":"2484734643","title":"Carisma Therapeutics Says Preclinical Data Support Potential of Engineered Macrophages to Treat Liver Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2484734643","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484734643?lang=en_us&edition=fundamental","pubTime":"2024-11-18 17:04","pubTimestamp":1731920652,"startTime":"0","endTime":"0","summary":"Carisma Therapeutics  said Sunday that new preclinical data showed the potential of the company's engineered macrophages in multiple liver fibrosis models.Results of the study showed that the engineered macrophages significantly reduced liver fibrosis and hepatic stellate cell activation. The engineered macrophages were also well tolerated in the study, the company said.The company anticipates to nominate a development candidate for its liver fibrosis program in Q1 2025.Price: 1.0407, Change: -0.01, Percent Change: -0.89","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","CARM"],"gpt_icon":0},{"id":"2484687062","title":"Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2484687062","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484687062?lang=en_us&edition=fundamental","pubTime":"2024-11-17 20:30","pubTimestamp":1731846600,"startTime":"0","endTime":"0","summary":"New preclinical results support the anti-fibrotic potential of engineered macrophages in multiple fibrosis models. PHILADELPHIA, Nov. 17, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today presented promising preclinical data on engineered macrophages for treating liver fibrosis at the American Association for the Study of Liver Diseases  The Liver Meeting 2024. These results underscore the pre-clinical efficacy of Carisma's engineered macrophages in multiple liver fibrosis models and offer a novel, off-the-shelf potential treatment option for patients with fibrotic liver disease including advanced metabolic dysfunction-associated steatohepatitis .\"We are pleased to present compelling preclinical data supporting the therapeutic potential of our engineered macrophages to address a critical unmet need in liver fibrosis, which is found in advanced stages of MASH,\" said Michael ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/aGF3Q8ckRSfUVydORVClCw--~B/aD0xMDQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ffc8d7a6f9a8e6fb35c642709403ae67","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/aGF3Q8ckRSfUVydORVClCw--~B/aD0xMDQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ffc8d7a6f9a8e6fb35c642709403ae67"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/carisma-therapeutics-presents-promising-preclinical-123000147.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/carisma-therapeutics-presents-promising-preclinical-123000147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CARM"],"gpt_icon":0},{"id":"2482644137","title":"Carisma Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2482644137","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482644137?lang=en_us&edition=fundamental","pubTime":"2024-11-12 06:20","pubTimestamp":1731363600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CARM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2024 17:20 ET (22:20 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARM"],"gpt_icon":0},{"id":"2482221461","title":"Optimistic Buy Rating for Carisma Therapeutics Amid Promising CAR-Myeloid Developments and Strong Financial Standing","url":"https://stock-news.laohu8.com/highlight/detail?id=2482221461","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482221461?lang=en_us&edition=fundamental","pubTime":"2024-11-11 14:15","pubTimestamp":1731305716,"startTime":"0","endTime":"0","summary":"Jack Allen, an analyst from Robert W. Baird, maintained the Buy rating on Carisma Therapeutics (CARM – Research Report). The associated price targe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/optimistic-buy-rating-for-carisma-therapeutics-amid-promising-car-myeloid-developments-and-strong-financial-standing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/optimistic-buy-rating-for-carisma-therapeutics-amid-promising-car-myeloid-developments-and-strong-financial-standing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CARM","CAR"],"gpt_icon":0},{"id":"2482297232","title":"Carisma Therapeutics Third Quarter 2024 Earnings: Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2482297232","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482297232?lang=en_us&edition=fundamental","pubTime":"2024-11-10 22:28","pubTimestamp":1731248883,"startTime":"0","endTime":"0","summary":"Carisma Therapeutics ( NASDAQ:CARM ) Third Quarter 2024 Results Key Financial Results Revenue: US$3.39m (down 12% from...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-carm/carisma-therapeutics/news/carisma-therapeutics-third-quarter-2024-earnings-misses-expe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CARM"],"gpt_icon":0},{"id":"2481174631","title":"BRIEF-Carisma Unveils Pre-Clinical Data On Anti-GPC3 In Vivo CAR-M Therapy For Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2481174631","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481174631?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:39","pubTimestamp":1731069540,"startTime":"0","endTime":"0","summary":"Nov 8  - Carisma Therapeutics Inc   :   * CARISMA UNVEILS PROMISING PRE-CLINICAL DATA ON ANTI-GPC3 IN VIVO CAR-M THERAPY FOR HEPATOCELLULAR CARCINOMA   * CARISMA -ANTI-GPC3 IN VIVO CAR-M THERAPY WELL TOLERATED IN MOUSE MODELS, HIGHLIGHTING ITS POTENTIAL AS AN OFF--SHELF TREATMENT FOR GPC3+ SOLID TUMORSSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4532","BK4548","BK4551","BK4568","BK4139","BK4230","BK4533","BK4534","BK4588","BK4501","CARM","BK4585","CAR","MRNA"],"gpt_icon":0},{"id":"2481171150","title":"Carisma Unveils Promising Pre-Clinical Data on Anti-Gpc3 in Vivo Car-M Therapy for Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2481171150","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481171150?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:30","pubTimestamp":1731069008,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nFWN3MF1SM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4568","CARM","BK4548","BK4533","BK4534","MRNA","BK4551","BK4585","BK4501","BK4532","BK4588"],"gpt_icon":0},{"id":"2481171130","title":"Carisma -Anti-Gpc3 in Vivo Car-M Therapy Well Tolerated in Mouse Models, Highlighting Its Potential as an off--Shelf Treatment for Gpc3+ Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2481171130","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481171130?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:30","pubTimestamp":1731069008,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nFWN3MF1SM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","BK4585","BK4501","CARM","MRNA","BK4551","BK4139","BK4533","BK4548","BK4568","BK4532","BK4588"],"gpt_icon":0},{"id":"2481293174","title":"Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2481293174","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481293174?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:30","pubTimestamp":1731069000,"startTime":"0","endTime":"0","summary":"New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma . PHILADELPHIA, Nov. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte  therapy for hepatocellular carcinoma , developed in collaboration with Moderna, Inc. . The data demonstrated that the development candidate can successfully create CAR-M directly in vivo, reprogramming endogenous myeloid cells to target and destroy Glypican-3 , expressing cancer cells.\"These preclinical data highlights the successful application of our mRNA/LNP platform in enabling in vivo cell therapy,\" saidLin Guey, PhD, CSO ofTherapeutic Research Ventures, Moderna.\"We look forward to further advancing the anti-GPC3 in vivo CAR-M therapy for HCC patients an","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/aGF3Q8ckRSfUVydORVClCw--~B/aD0xMDQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ffc8d7a6f9a8e6fb35c642709403ae67","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/aGF3Q8ckRSfUVydORVClCw--~B/aD0xMDQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ffc8d7a6f9a8e6fb35c642709403ae67"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/carisma-unveils-promising-pre-clinical-123000531.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/carisma-unveils-promising-pre-clinical-123000531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4022","MRNA","HCC","CAR","BK4139","CARM","BK4230","BK4006"],"gpt_icon":0},{"id":"2481184690","title":"Carisma Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481184690","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481184690?lang=en_us&edition=fundamental","pubTime":"2024-11-07 23:10","pubTimestamp":1730992216,"startTime":"0","endTime":"0","summary":"* Carisma Therapeutics Inc    reported a quarterly adjusted loss of 31 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -53 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Carisma Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARM"],"gpt_icon":0},{"id":"2481907079","title":"Carisma Therapeutics Is Maintained at Buy by EF Hutton","url":"https://stock-news.laohu8.com/highlight/detail?id=2481907079","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481907079?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:43","pubTimestamp":1730986980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CARM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2024 08:43 ET (13:43 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARM"],"gpt_icon":0},{"id":"2481909085","title":"CARISMA Therapeutics' Q3 Cash And Cash Equivalents Of $26.9M Expected To Fund The Company Into The Third Quarter Of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2481909085","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481909085?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:56","pubTimestamp":1730984167,"startTime":"0","endTime":"0","summary":"CARISMA Therapeutics' Q3 Cash And Cash Equivalents Of $26.9M Expected To Fund The Company Into The Third Quarter Of 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/24/11/41804806/carisma-therapeutics-q3-cash-and-cash-equivalents-of-26-9m-expected-to-fund-the-company-into-the-","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","CARM"],"gpt_icon":0},{"id":"2481808906","title":"Carisma Therapeutics Inc: Cash & Cash Equivalents of $26.9 Million Expected to Fund Co Into Q3 of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2481808906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481808906?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:30","pubTimestamp":1730982609,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUABRZZ9K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CARM","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":69,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CARM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-31","symbol":"CARM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-07","symbol":"CARM","fiscalQuarterEnding":"2024/09","expectedEps":-0.31,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.31},{"market":"US","date":"2024-08-08","symbol":"CARM","fiscalQuarterEnding":"2024/06","expectedEps":-0.36,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"pre","actualEps":-0.27},{"market":"US","date":"2024-05-09","symbol":"CARM","fiscalQuarterEnding":"2024/03","expectedEps":-0.37,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-0.46},{"market":"US","date":"2024-04-01","symbol":"CARM","fiscalQuarterEnding":"2023/12","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1711944000000,"reportTimeType":"pre","actualEps":-0.52}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CARM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CARM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.3333,"hold":0.6667,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.6667,"analysts":3,"updateTime":1736481600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CARM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CARM","date":"2025-04-23","current":-0.146418,"percent":0.978218,"low":-5.12389,"twenty":-2.807425,"median":-1.025276,"eighty":-0.526861,"high":-0.121612,"avg":-1.457762,"sd":1.251979,"marketCap":8854897},"quantilePoints":[{"date":"2023-03-10","current":-3.207819,"twenty":-3.598679,"median":-3.563146,"eighty":-3.34995,"marketCap":130827684},{"date":"2023-03-17","current":-3.079506,"twenty":-3.4526,"median":-3.183143,"eighty":-3.113065,"marketCap":125594576},{"date":"2023-03-24","current":-3.168338,"twenty":-3.255196,"median":-3.118987,"eighty":-2.889997,"marketCap":129217477},{"date":"2023-03-31","current":-3.059765,"twenty":-3.192027,"median":-3.094311,"eighty":-2.917634,"marketCap":124789464},{"date":"2023-04-06","current":-2.901842,"twenty":-3.166364,"median":-3.069635,"eighty":-2.909738,"marketCap":118348718},{"date":"2023-04-14","current":-2.038178,"twenty":-3.15452,"median":-3.049895,"eighty":-2.846569,"marketCap":124789464},{"date":"2023-04-21","current":-2.807425,"twenty":-3.134779,"median":-2.975868,"eighty":-2.644371,"marketCap":171887423},{"date":"2023-04-28","current":-2.656206,"twenty":-3.118987,"median":-2.921582,"eighty":-2.629907,"marketCap":162628850},{"date":"2023-05-05","current":-3.353131,"twenty":-3.138727,"median":-2.901842,"eighty":-2.636481,"marketCap":205298796},{"date":"2023-05-12","current":-3.714743,"twenty":-3.207819,"median":-2.975868,"eighty":-2.656206,"marketCap":227438862},{"date":"2023-05-19","current":-3.030967,"twenty":-3.286781,"median":-3.049895,"eighty":-2.67593,"marketCap":185574010},{"date":"2023-05-26","current":-2.591641,"twenty":-3.286781,"median":-3.040431,"eighty":-2.67593,"marketCap":193222396},{"date":"2023-05-31","current":-2.694227,"twenty":-3.263353,"median":-3.030967,"eighty":-2.68119,"marketCap":200870783},{"date":"2023-06-08","current":-3.196357,"twenty":-3.345241,"median":-3.05483,"eighty":-2.690109,"marketCap":238307622},{"date":"2023-06-16","current":-3.995447,"twenty":-3.440944,"median":-3.079506,"eighty":-2.697142,"marketCap":297884528},{"date":"2023-06-23","current":-4.924118,"twenty":-3.563146,"median":-3.109117,"eighty":-2.708804,"marketCap":367122553},{"date":"2023-06-30","current":-4.843129,"twenty":-3.680142,"median":-3.118987,"eighty":-2.724583,"marketCap":361084354},{"date":"2023-07-07","current":-4.55157,"twenty":-3.877471,"median":-3.142738,"eighty":-2.756142,"marketCap":339346834},{"date":"2023-07-14","current":-4.859327,"twenty":-4.187278,"median":-3.168688,"eighty":-2.787908,"marketCap":362291994},{"date":"2023-07-21","current":-4.778338,"twenty":-4.47382,"median":-3.201911,"eighty":-2.80318,"marketCap":356253794},{"date":"2023-07-28","current":-3.088372,"twenty":-4.47382,"median":-3.204865,"eighty":-2.820495,"marketCap":230256689},{"date":"2023-08-04","current":-2.931794,"twenty":-4.419828,"median":-3.169038,"eighty":-2.837256,"marketCap":218582836},{"date":"2023-08-11","current":-3.204157,"twenty":-4.40147,"median":-3.163403,"eighty":-2.847531,"marketCap":238889130},{"date":"2023-08-18","current":-3.2042,"twenty":-4.345825,"median":-3.178891,"eighty":-2.857739,"marketCap":255003068},{"date":"2023-08-25","current":-3.305439,"twenty":-4.268267,"median":-3.186484,"eighty":-2.865146,"marketCap":263060037},{"date":"2023-09-01","current":-3.502854,"twenty":-4.157424,"median":-3.201911,"eighty":-2.876062,"marketCap":278771127},{"date":"2023-09-08","current":-2.515778,"twenty":-4.060238,"median":-3.194076,"eighty":-2.855427,"marketCap":200215679},{"date":"2023-09-15","current":-2.432256,"twenty":-3.993621,"median":-3.168688,"eighty":-2.801058,"marketCap":193568680},{"date":"2023-09-22","current":-2.014647,"twenty":-3.960313,"median":-3.153581,"eighty":-2.700058,"marketCap":160333683},{"date":"2023-09-29","current":-2.267744,"twenty":-3.8898,"median":-3.140732,"eighty":-2.664096,"marketCap":180476105},{"date":"2023-10-06","current":-2.217124,"twenty":-3.832117,"median":-3.116439,"eighty":-2.601687,"marketCap":176447621},{"date":"2023-10-13","current":-1.670436,"twenty":-3.766542,"median":-3.099247,"eighty":-2.527927,"marketCap":132939988},{"date":"2023-10-20","current":-1.490738,"twenty":-3.697443,"median":-3.079506,"eighty":-2.412515,"marketCap":118638868},{"date":"2023-10-27","current":-1.437587,"twenty":-3.680142,"median":-3.059765,"eighty":-2.384168,"marketCap":114408959},{"date":"2023-11-03","current":-1.52364,"twenty":-3.648235,"median":-3.044837,"eighty":-2.294066,"marketCap":121257383},{"date":"2023-11-10","current":-1.289683,"twenty":-3.626379,"median":-3.030967,"eighty":-2.181185,"marketCap":106605233},{"date":"2023-11-17","current":-1.230331,"twenty":-3.57499,"median":-3.018182,"eighty":-2.131577,"marketCap":101699151},{"date":"2023-11-24","current":-1.20592,"twenty":-3.545193,"median":-3.001984,"eighty":-2.056155,"marketCap":99681310},{"date":"2023-12-01","current":-1.171744,"twenty":-3.518998,"median":-2.961063,"eighty":-1.996997,"marketCap":96856334},{"date":"2023-12-08","current":-1.244978,"twenty":-3.505518,"median":-2.916818,"eighty":-1.804922,"marketCap":102909855},{"date":"2023-12-15","current":-1.323094,"twenty":-3.478557,"median":-2.8913,"eighty":-1.666386,"marketCap":109366944},{"date":"2023-12-22","current":-1.415857,"twenty":-3.456285,"median":-2.864682,"eighty":-1.547938,"marketCap":117034737},{"date":"2023-12-29","current":-1.498855,"twenty":-3.452235,"median":-2.850805,"eighty":-1.518424,"marketCap":123895394},{"date":"2024-01-05","current":-1.332858,"twenty":-3.452235,"median":-2.835914,"eighty":-1.497232,"marketCap":110174080},{"date":"2024-01-12","current":-1.269389,"twenty":-3.446589,"median":-2.796813,"eighty":-1.454396,"marketCap":104927695},{"date":"2024-01-19","current":-1.147332,"twenty":-3.444905,"median":-2.728528,"eighty":-1.425858,"marketCap":94838494},{"date":"2024-01-26","current":-1.078981,"twenty":-3.433385,"median":-2.693587,"eighty":-1.391796,"marketCap":89188541},{"date":"2024-02-02","current":-1.054569,"twenty":-3.417727,"median":-2.67593,"eighty":-1.356293,"marketCap":87170700},{"date":"2024-02-09","current":-1.025276,"twenty":-3.411974,"median":-2.633194,"eighty":-1.311376,"marketCap":84749292},{"date":"2024-02-16","current":-1.118039,"twenty":-3.392354,"median":-2.591641,"eighty":-1.282083,"marketCap":92417085},{"date":"2024-02-23","current":-1.210802,"twenty":-3.36891,"median":-2.530964,"eighty":-1.255719,"marketCap":100084878},{"date":"2024-03-01","current":-1.259624,"twenty":-3.352277,"median":-2.52084,"eighty":-1.242048,"marketCap":104120559},{"date":"2024-03-08","current":-1.210802,"twenty":-3.33607,"median":-2.432256,"eighty":-1.242048,"marketCap":100084878},{"date":"2024-03-15","current":-1.20592,"twenty":-3.310385,"median":-2.368982,"eighty":-1.230331,"marketCap":99681310},{"date":"2024-03-22","current":-1.225449,"twenty":-3.305439,"median":-2.313301,"eighty":-1.217637,"marketCap":101295583},{"date":"2024-03-28","current":-1.093627,"twenty":-3.303414,"median":-2.267744,"eighty":-1.211778,"marketCap":90399245},{"date":"2024-04-05","current":-0.918078,"twenty":-3.294961,"median":-2.200673,"eighty":-1.20592,"marketCap":79761665},{"date":"2024-04-12","current":-0.946768,"twenty":-3.292191,"median":-2.166505,"eighty":-1.196155,"marketCap":82254217},{"date":"2024-04-19","current":-0.817663,"twenty":-3.275067,"median":-2.117151,"eighty":-1.191273,"marketCap":71037733},{"date":"2024-04-26","current":-0.784191,"twenty":-3.224132,"median":-2.060205,"eighty":-1.182484,"marketCap":68129755},{"date":"2024-05-03","current":-0.765069,"twenty":-3.207095,"median":-2.026413,"eighty":-1.169791,"marketCap":66468390},{"date":"2024-05-10","current":-0.772389,"twenty":-3.204191,"median":-1.994399,"eighty":-1.158073,"marketCap":62729543},{"date":"2024-05-17","current":-0.700776,"twenty":-3.203708,"median":-1.857372,"eighty":-1.134639,"marketCap":56913559},{"date":"2024-05-24","current":-0.64451,"twenty":-3.2008,"median":-1.731179,"eighty":-1.122921,"marketCap":52343857},{"date":"2024-05-31","current":-0.670086,"twenty":-3.196357,"median":-1.670436,"eighty":-1.108274,"marketCap":54420994},{"date":"2024-06-07","current":-0.567782,"twenty":-3.194076,"median":-1.607162,"eighty":-1.093627,"marketCap":46112445},{"date":"2024-06-14","current":-0.598473,"twenty":-3.181928,"median":-1.543888,"eighty":-1.053593,"marketCap":48605010},{"date":"2024-06-21","current":-0.516631,"twenty":-3.172979,"median":-1.518482,"eighty":-1.036017,"marketCap":41958171},{"date":"2024-06-28","current":-0.65474,"twenty":-3.169038,"median":-1.515944,"eighty":-1.025276,"marketCap":53174712},{"date":"2024-07-05","current":-0.711007,"twenty":-3.168478,"median":-1.494797,"eighty":-1.008676,"marketCap":57744414},{"date":"2024-07-12","current":-0.613819,"twenty":-3.160442,"median":-1.473021,"eighty":-0.961113,"marketCap":49851292},{"date":"2024-07-15","current":-0.613819,"twenty":-3.158468,"median":-1.463968,"eighty":-0.961113,"marketCap":49851292},{"date":"2024-08-02","current":-0.526861,"twenty":-3.157491,"median":-1.454915,"eighty":-0.949637,"marketCap":42789026},{"date":"2024-08-09","current":-0.516269,"twenty":-3.151556,"median":-1.435056,"eighty":-0.919034,"marketCap":37430012},{"date":"2024-08-16","current":-0.601678,"twenty":-3.143313,"median":-1.406092,"eighty":-0.857437,"marketCap":43622223},{"date":"2024-08-23","current":-0.681901,"twenty":-3.141936,"median":-1.391738,"eighty":-0.812881,"marketCap":49438520},{"date":"2024-08-30","current":-0.624599,"twenty":-3.134779,"median":-1.362152,"eighty":-0.787061,"marketCap":45284022},{"date":"2024-09-06","current":-0.571021,"twenty":-3.118987,"median":-1.347505,"eighty":-0.779414,"marketCap":41399567},{"date":"2024-09-13","current":-0.561852,"twenty":-3.116439,"median":-1.327976,"eighty":-0.772389,"marketCap":40734847},{"date":"2024-09-20","current":-0.56191,"twenty":-3.115616,"median":-1.289683,"eighty":-0.757043,"marketCap":40739002},{"date":"2024-09-27","current":-0.565921,"twenty":-3.109117,"median":-1.281595,"eighty":-0.726352,"marketCap":41029817},{"date":"2024-10-04","current":-0.532914,"twenty":-3.089376,"median":-1.269389,"eighty":-0.716283,"marketCap":38636826},{"date":"2024-10-11","current":-0.534633,"twenty":-3.088372,"median":-1.264507,"eighty":-0.710553,"marketCap":38761461},{"date":"2024-10-18","current":-0.572912,"twenty":-3.079506,"median":-1.259624,"eighty":-0.681901,"marketCap":41536666},{"date":"2024-10-25","current":-0.571766,"twenty":-3.059765,"median":-1.247419,"eighty":-0.66497,"marketCap":41453576},{"date":"2024-10-31","current":-0.573026,"twenty":-3.059765,"median":-1.242536,"eighty":-0.658132,"marketCap":41544975},{"date":"2024-11-08","current":-0.67071,"twenty":-3.051869,"median":-1.235213,"eighty":-0.64752,"marketCap":42791324},{"date":"2024-11-15","current":-0.611388,"twenty":-3.041802,"median":-1.230331,"eighty":-0.646918,"marketCap":39006577},{"date":"2024-11-22","current":-0.554792,"twenty":-3.039779,"median":-1.220566,"eighty":-0.633045,"marketCap":35395742},{"date":"2024-11-29","current":-0.55898,"twenty":-3.034492,"median":-1.215684,"eighty":-0.613819,"marketCap":35662943},{"date":"2024-12-06","current":-0.518277,"twenty":-3.030967,"median":-1.210802,"eighty":-0.608704,"marketCap":33066086},{"date":"2024-12-13","current":-0.317379,"twenty":-3.023296,"median":-1.20592,"eighty":-0.598473,"marketCap":20248802},{"date":"2024-12-20","current":-0.288913,"twenty":-3.018182,"median":-1.201037,"eighty":-0.588243,"marketCap":18432673},{"date":"2024-12-27","current":-0.289241,"twenty":-3.013863,"median":-1.193714,"eighty":-0.580505,"marketCap":18453548},{"date":"2025-01-03","current":-0.287997,"twenty":-3.005224,"median":-1.191273,"eighty":-0.578756,"marketCap":18374222},{"date":"2025-01-10","current":-0.310246,"twenty":-2.996585,"median":-1.191273,"eighty":-0.578756,"marketCap":19793726},{"date":"2025-01-17","current":-0.298729,"twenty":-2.990674,"median":-1.18639,"eighty":-0.573026,"marketCap":19058924},{"date":"2025-01-24","current":-0.289306,"twenty":-2.966985,"median":-1.176626,"eighty":-0.573026,"marketCap":18457723},{"date":"2025-01-31","current":-0.326541,"twenty":-2.945271,"median":-1.170523,"eighty":-0.572878,"marketCap":20833304},{"date":"2025-02-07","current":-0.327195,"twenty":-2.9337,"median":-1.166861,"eighty":-0.571342,"marketCap":20875054},{"date":"2025-02-14","current":-0.310639,"twenty":-2.907832,"median":-1.155876,"eighty":-0.566563,"marketCap":19818776},{"date":"2025-02-21","current":-0.302786,"twenty":-2.901842,"median":-1.144891,"eighty":-0.562254,"marketCap":19317775},{"date":"2025-02-28","current":-0.2683,"twenty":-2.895517,"median":-1.132686,"eighty":-0.560993,"marketCap":17117544},{"date":"2025-03-07","current":-0.258484,"twenty":-2.885781,"median":-1.122921,"eighty":-0.558743,"marketCap":16491293},{"date":"2025-03-14","current":-0.262869,"twenty":-2.873042,"median":-1.118039,"eighty":-0.556127,"marketCap":16771018},{"date":"2025-03-21","current":-0.272096,"twenty":-2.864218,"median":-1.105833,"eighty":-0.552829,"marketCap":17359695},{"date":"2025-03-28","current":-0.234141,"twenty":-2.855427,"median":-1.093627,"eighty":-0.548512,"marketCap":14938189},{"date":"2025-04-04","current":-0.132616,"twenty":-2.845895,"median":-1.064334,"eighty":-0.541006,"marketCap":8020195},{"date":"2025-04-11","current":-0.137504,"twenty":-2.834573,"median":-1.044805,"eighty":-0.534289,"marketCap":8315831},{"date":"2025-04-17","current":-0.138817,"twenty":-2.820495,"median":-1.030158,"eighty":-0.527747,"marketCap":8395228},{"date":"2025-04-23","current":-0.146418,"twenty":-2.807425,"median":-1.025276,"eighty":-0.526861,"marketCap":8854897}],"updateTime":1745558115688}}}